CIBC Bancorp USA’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.26M Buy
22,088
+5,756
+35% +$336K ﹤0.01% 1054
2026
Q2
$949K Buy
16,332
+2,324
+17% +$126K ﹤0.01% 1117
2026
Q1
$814K Buy
+14,008
New +$760K ﹤0.01% 1087
2025
Q3
$440K Buy
+12,205
New +$404K ﹤0.01% 922

Other funds holding PCVX

CIBC Bancorp USA's PCVX Position: Q3 2026 in Review

CIBC Bancorp USA increased its Vaxcyte (PCVX) stake by 35% in Q3 2026, buying an estimated $336K and bringing the position to 22,088 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1054.

CIBC Bancorp USA first reported a position in PCVX in Q3 2025 and has held it in 4 quarters since. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • CIBC Bancorp USA held 22,088 shares of Vaxcyte worth $1.26M as of Q3 2026.
  • CIBC Bancorp USA bought 5,756 Vaxcyte shares in Q3 2026, an estimated $336K.
  • Vaxcyte made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1054 holding.
  • CIBC Bancorp USA first reported a position in Vaxcyte in Q3 2025 and has held it in 4 quarters since.
  • 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.